Last reviewed · How we verify
Steroids therapy
Steroids therapy involves the use of corticosteroids to suppress the immune system and reduce inflammation.
Steroids therapy involves the use of corticosteroids to suppress the immune system and reduce inflammation. Used for Rheumatoid arthritis, Multiple sclerosis, Asthma.
At a glance
| Generic name | Steroids therapy |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids work by binding to glucocorticoid receptors, which then translocate to the nucleus and regulate the expression of genes involved in inflammation and immune response. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Approved indications
- Rheumatoid arthritis
- Multiple sclerosis
- Asthma
- Allergic reactions
Common side effects
- Weight gain
- Insomnia
- Mood changes
- Increased blood pressure
- Osteoporosis
- Glucose intolerance
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Steroids therapy CI brief — competitive landscape report
- Steroids therapy updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI